Oruka Therapeutics (ORKA) – Investment Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Oruka Therapeutics (NASDAQ: ORKA):

• 7/15/2026 – Oruka Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/13/2026 – Oruka Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $151.00 price target on the stock.
• 7/1/2026 – Oruka Therapeutics had its price target raised by UBS Group AG from $100.00 to $130.00. They now have a “buy” rating on the stock.
• 6/30/2026 – Oruka Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 6/23/2026 – Oruka Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $120.00 price target on the stock.
• 6/13/2026 – Oruka Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/3/2026 – Oruka Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 6/2/2026 – Oruka Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $180.00 price target on the stock.
• 5/18/2026 – Oruka Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $120.00 price target on the stock.

Insider Buying and Selling at Oruka Therapeutics

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,947 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $69.28, for a total transaction of $550,568.16. Following the completion of the transaction, the insider owned 32,718 shares in the company, valued at $2,266,703.04. This trade represents a 19.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction on Monday, June 15th. The stock was sold at an average price of $69.69, for a total transaction of $120,494.01. Following the completion of the transaction, the chief executive officer directly owned 925,580 shares of the company’s stock, valued at $64,503,670.20. The trade was a 0.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 188,406 shares of company stock valued at $12,019,683. 23.49% of the stock is owned by company insiders.

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.